Drug intelligence / Profile preview

LKA651

Development stage: Phase 2
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

LKA651 is a monoclonal antibody that acts as an erythropoietin receptor modulator. It is primarily being investigated for the treatment of eye diseases, including diabetic macular edema. Initially developed by MorphoSys AG, it is currently in Phase 2 trials.

Other names: LKA-651LKA651LKA 651

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on LKA651.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LKA651.

Explore the full profile